Sep. 14, 2009
Center for AIDS Research at Emory To Serve as Local Host of AIDS Vaccine 2010
The Global HIV Vaccine Enterprise (the Enterprise) today announced that the Center for AIDS Research at Emory University (CFAR) will serve as Local Host of AIDS Vaccine 2010, the largest and most important global scientific conference focused on AIDS vaccine research.
AIDS 2010 is scheduled for Sept. 28 to Oct. 1, 2010. This annual international conference brings together scientists, community advocates, funders and policy makers from around the world to hear cutting edge scientific results, exchange new ideas, educate future leaders and engage a diverse community of scientists in the quest for an HIV vaccine.
AIDS Vaccine 2010 will feature daily plenary presentations by leading researchers, clinicians and community advocates, and oral and poster presentations of hundreds of research papers addressing every aspect of HIV vaccine development and testing. The conference is expected to attract more than 1,000 researchers, clinicians and community advocates from around the world to Atlanta.
Eric Hunter, PhD, Georgia Research Alliance eminent scholar and co-director, Center for AIDS Research at Emory University, will chair AIDS Vaccine 2010 with support from the following co-chairs: James Curran, MD, MPH, dean, Rollins School of Public Health and co-director, Center for AIDS Research, Emory University; Carlos del Rio, MD, Hubert professor and chair of the Hubert Department of Global Health, Rollins School of Public Health and co-director, Center for AIDS Research, Emory University; and Harriet Robinson, PhD, senior vice president of research and development, GeoVax, former director, division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University.
"The Center for AIDS Research at Emory University is pleased to host the AIDS Vaccine 2010 conference in Atlanta," says Eric Hunter, PhD, whose research is conducted at the Emory Vaccine Center. Because Atlanta is the epicenter for the HIV/AIDS pandemic in the Southeast, the development of a viable vaccine is a very relevant objective for our community. The devastation of HIV/AIDS is well known, and the need for continued scientific inquiry and global awareness of the disease remains critical in the quest for an effective HIV vaccine."
AIDS Vaccine 2010 aims to help cultivate a global network of scientific talent to carry the field of HIV vaccine research into the future. AIDS Vaccine 2010 will welcome a large cohort of promising early career scientists both nationally and internationally through conference scholarships and travel support.
Alan Bernstein, PhD, executive director, Global HIV Vaccine Enterprise, says, "The Global HIV Vaccine Enterprise is committed to accelerating the search for a safe and effective vaccine through scientific collaboration and global initiatives that bring together the world's best researchers, scientific organizations, advocates, funders and policy makers for common purpose. Our annual AIDS Vaccine conference is one such initiative and we look forward to collaborating with the Center for AIDS Research at Emory University to plan and implement the premier conference dedicated to HIV vaccine research."
AIDS Vaccine 2009, with the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) serving as Local Host, will be held in Paris, France from October 19 to 22, 2009. AIDS Vaccine 2008 was held in Cape Town, South Africa.
More information on the AIDS Vaccine conference is available at www.hivvaccineenterprise.org/conference/2009/index.aspx.
The Global HIV Vaccine Enterprise (the Enterprise) is a one-of-a-kind alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. The Enterprise, comprised of top research, funding, advocacy and other stakeholder organizations, develops and drives implementation of the Scientific Strategic Plan for HIV vaccine development. In support of this Plan, Enterprise stakeholders are setting shared research agendas, creating new structures for information sharing, developing new tools to harmonize global research efforts, and bringing new organizations, expertise and money to the challenge. The Enterprise organizes the world's leading HIV vaccine research conference, AIDS Vaccine, annually. For more information, please visit www.hivvaccineenterprise.org.
The Center for AIDS Research at Emory University (CFAR) is one of 20 National Institutes of Health funded centers across the United States. The CFAR at Emory facilitates clinical, prevention, vaccine and basic science HIV/AIDS research for more than 120 investigators at Emory and its Atlanta partner institutions. The Emory Vaccine Center (EVC) supports strong pre-clinical and clinical HIV vaccine research programs. Emory University, ranked as one of the country's top national universities, encompasses nine undergraduate, graduate and professional schools with a total enrollment of 12,755 students. For more information, please visit www.emory.edu, www.cfar.emory.edu and http://vaccines.emory.edu.
Contact at Global HIV Vaccine Enterprise is Jennifer Brunet, External Relations Manager, firstname.lastname@example.org, Phone: +1.212.461.3693
The Robert W. Woodruff Health Sciences Center of Emory University is an academic health science and service center focused on missions of teaching, research, health care and public service. Its components include schools of medicine, nursing, and public health; Yerkes National Primate Research Center; the Emory Winship Cancer Institute; and Emory Healthcare, the largest, most comprehensive health system in Georgia. The Woodruff Health Sciences Center has a $2.3 billion budget, 17,000 employees, 2,300 full-time and 1,900 affiliated faculty, 4,300 students and trainees, and a $4.9 billion economic impact on metro Atlanta.